An AARS enzyme performs two coordinated recognitions: it must bind the correct amino acid and the correct tRNA identity, then join them using ATP. The product is an aminoacyl-tRNA—a tRNA “charged” with an amino acid.

Key point: the ribosome mainly checks codon–anticodon pairing. If a tRNA is mischarged, the ribosome can still accept it—meaning the code is enforced upstream by AARS.

Amino acid + ATP + tRNA  --(AARS)-->  aminoacyl-tRNA + AMP + PPi

Then:
mRNA codon + (matching) tRNA anticodon  --(ribosome)-->  amino acid inserted into the growing chain

In modern cells, the charging step is an energy-expensive commitment to meaning: the system pays ATP to reduce ambiguity.

tRNAs carry both a codon-matching anticodon and a set of structural “identity elements” that allow the correct AARS to recognize them. Recognition is distributed across features such as:

• Acceptor stem geometry and base pairs
• Anticodon loop (sometimes used, sometimes not the primary cue)
• Discriminator base (often near the acceptor end)
• Overall folding/shape of the tRNA

This matters because many amino acids correspond to multiple codons, which can imply multiple tRNAs. The “correctness” of translation depends on AARS reliably choosing the right tRNA among dozens of similar molecules.

Some amino acids are chemically similar. That makes misactivation a real risk. Several AARS enzymes include an editing function: a second site can hydrolyze incorrectly attached amino acids (or misactivated intermediates) before they reach the ribosome.

A canonical example is the isoleucine/valine problem: they differ subtly, but the consequences of systematic substitution can be severe. Editing is a way of paying extra biochemical cost to avoid runaway noise.

Why this matters for origins: an early system has to be “accurate enough” for proteins to be stably inherited. If the error rate is too high, any emergent catalytic advantage is washed out by noise.

You cited an overall error rate on the order of ~1 in 10,000 bindings as a reference point for modern systems. The exact number varies by enzyme and context, but the qualitative point holds: translation requires error control.

Below is your Phase-2 table, retained as a “scale reminder.” Even if we avoid exact organism-specific counts, the structural point is stable: many distinct enzymes exist, and they are not tiny.

The point isn’t that modern counts must be projected back unchanged; it’s that translation fidelity depends on a set of typed recognitions. If even one amino acid lacks a workable charging path, translation can stall at any codon that requires it.

Your broader argument is that origins-of-life models have to account not only for “informational polymers” but for a translation system that can reliably convert code into functional catalysts fast enough to outrun equilibrium.

AARS intensify the bootstrapping problem: they are proteins produced by translation, yet translation depends on their charging rule. Proposed bridges (ribozymes, peptidated ribozymes, simplified codes, urzyme hypotheses) are attempts to reduce the initial enforcement burden—but the system still requires coherence: a stable mapping must exist early enough for cumulative selection to operate on proteins at all.

This is the point where your simulation demo naturally fits: it’s a way of asking whether stepwise movement in sequence space can plausibly preserve “enough” interim coherence to keep a mapping from diffusing into noise.